Experimental Drug CS18 Shows Promise in Overcoming Cancer Treatment Resistance
Developed by researchers at Baylor College of Medicine, the experimental small molecule drug CS18 disrupts a master regulatory switch called TopBP1, effectively dismantling the survival defenses of hard-to-treat cancer cells. … Read More